BACKGROUND: Amyloid light chain (AL) amyloidosis is a rare disease with poor prognosis and limited therapeutic alternatives. Recently, one clinical case with cardiac involvement, as well as a compelling evidence of green tea polyphenol, epigallocatechin-3-gallate (EGCG), inducing the formation of benign aggregation products that do not polymerize into fibrils were published. This is a report of the cardiac effects of green tea consumption in these patients. METHODS: Patients with known cardiac involvement in AL amyloidosis were examined by routine cardiovascular examinations that took place every 3-6 months. Of 59 patients with cardiac involvement, 11 revealed a decrease of at least 2 mm of interventricular wall thickness, after initiation of regular green tea consumption (GT). A matched historic control group (n = 22) was selected. Comprehensive echocardiography was conducted at every control examination and analyzed offline by two independent examiners. RESULTS: GT patients showed an improvement in New York Heart Association (NYHA) class from a median of 3 (25th, 75th percentiles: 2, 3) to 2 (2, 3), P = 0.038. Septal thickness decreased from 18 (18, 20) to 16 (16, 17) mm, P = 0.021. Left ventricular mass index decreased from 175 (154, 180) to 133 (128, 154) g/m(2), P = 0.007. Comparing both groups, an increase in left ventricular ejection fraction could be found in the GT group, 65 (51, 73) versus 53 (47, 59)%, P = 0.012. These changes could not be observed in the control group. CONCLUSION: Consumption of green tea polyphenol EGCG in patients with cardiac involvement with AL amyloidosis causes a significant decrease in left ventricular wall thickness and mass, as well as an improvement in NYHA functional classification and left ventricular ejection fraction.
BACKGROUND: Amyloid light chain (AL) amyloidosis is a rare disease with poor prognosis and limited therapeutic alternatives. Recently, one clinical case with cardiac involvement, as well as a compelling evidence of green tea polyphenol, epigallocatechin-3-gallate (EGCG), inducing the formation of benign aggregation products that do not polymerize into fibrils were published. This is a report of the cardiac effects of green tea consumption in these patients. METHODS:Patients with known cardiac involvement in AL amyloidosis were examined by routine cardiovascular examinations that took place every 3-6 months. Of 59 patients with cardiac involvement, 11 revealed a decrease of at least 2 mm of interventricular wall thickness, after initiation of regular green tea consumption (GT). A matched historic control group (n = 22) was selected. Comprehensive echocardiography was conducted at every control examination and analyzed offline by two independent examiners. RESULTS: GT patients showed an improvement in New York Heart Association (NYHA) class from a median of 3 (25th, 75th percentiles: 2, 3) to 2 (2, 3), P = 0.038. Septal thickness decreased from 18 (18, 20) to 16 (16, 17) mm, P = 0.021. Left ventricular mass index decreased from 175 (154, 180) to 133 (128, 154) g/m(2), P = 0.007. Comparing both groups, an increase in left ventricular ejection fraction could be found in the GT group, 65 (51, 73) versus 53 (47, 59)%, P = 0.012. These changes could not be observed in the control group. CONCLUSION: Consumption of green tea polyphenolEGCG in patients with cardiac involvement with AL amyloidosis causes a significant decrease in left ventricular wall thickness and mass, as well as an improvement in NYHA functional classification and left ventricular ejection fraction.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Masood A Shammas; Paola Neri; Hemanta Koley; Ramesh B Batchu; Robert C Bertheau; Vidit Munshi; Rao Prabhala; Mariateresa Fulciniti; Yu Tzu Tai; Steven P Treon; Raj K Goyal; Kenneth C Anderson; Nikhil C Munshi Journal: Blood Date: 2006-06-29 Impact factor: 22.113
Authors: Susanne M Henning; Yantao Niu; Yong Liu; Nicolas H Lee; Yukihiko Hara; Gail D Thames; Rosario R Minutti; Catherine L Carpenter; Hejing Wang; David Heber Journal: J Nutr Biochem Date: 2005-10 Impact factor: 6.048
Authors: Kavon Rezai-Zadeh; Doug Shytle; Nan Sun; Takashi Mori; Huayan Hou; Deborah Jeanniton; Jared Ehrhart; Kirk Townsend; Jin Zeng; David Morgan; John Hardy; Terrence Town; Jun Tan Journal: J Neurosci Date: 2005-09-21 Impact factor: 6.167
Authors: A L Klein; L K Hatle; C P Taliercio; C L Taylor; R A Kyle; K R Bailey; J B Seward; A J Tajik Journal: J Am Coll Cardiol Date: 1990-11 Impact factor: 24.094
Authors: H-H Sherry Chow; Iman A Hakim; Donna R Vining; James A Crowell; James Ranger-Moore; Wade M Chew; Catherine A Celaya; Steven R Rodney; Yukihiko Hara; David S Alberts Journal: Clin Cancer Res Date: 2005-06-15 Impact factor: 12.531
Authors: Ilona Hauber; Heinrich Hohenberg; Barbara Holstermann; Werner Hunstein; Joachim Hauber Journal: Proc Natl Acad Sci U S A Date: 2009-05-18 Impact factor: 11.205
Authors: Fabian aus dem Siepen; Sebastian J Buss; Florian Andre; Sebastian Seitz; Evangelos Giannitsis; Henning Steen; Hugo A Katus; Arnt V Kristen Journal: Clin Res Cardiol Date: 2015-02-18 Impact factor: 5.460
Authors: Sebastian J Buss; Derliz Mereles; Mostafa Emami; Grigorios Korosoglou; Johannes H Riffel; Diane Bertel; Stefan O Schonland; Ute Hegenbart; Hugo A Katus; Stefan E Hardt Journal: Clin Res Cardiol Date: 2011-12-04 Impact factor: 5.460